Amgen Inc. (AMGN)
Will Amgen (AMGN) Beat Estimates Again in Its Next Earnings Report?
Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know
Amgen (AMGN) closed the most recent trading day at $355.25, moving 1.44% from the previous trading session.
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Jim Cramer Calls Biotech “The Hottest Group in the Market” as He Predicts “Deals Are Going to Be Flooding the Market”
On CNBC's Mad Dash segment on Monday, July 6, 2026, Jim Cramer made one of his most bullish biotech calls in years, arguing that the sector could be entering a new wave of mergers and acquisitions as the regulatory environment becomes more favorable for dealmaking.
Amgen (AMGN) Stock Dips While Market Gains: Key Facts
Amgen (AMGN) closed the most recent trading day at $366.44, moving 2.06% from the previous trading session.
Amgen (AMGN) Upgraded to Buy: What Does It Mean for the Stock?
Amgen (AMGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Judge blocks Colorado's first-of-its-kind price cap on Amgen's Enbrel
A federal judge on Wednesday blocked Colorado from capping the price of Amgen's blockbuster arthritis drug Enbrel, a first-of-its-kind move by a U.S. state.
Amgen or Biogen: Which Biotech Stock Appears Better Poised?
AMGN stands out compared to Biogen given its broader product portfolio, pipeline depth and steadier growth outlook despite patent and competition risks.
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know
Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
EMA recommends revoking marketing authorisation for Amgen's rare-disease drug
The European Medicines Agency on Friday recommended revoking the marketing authorisation for Amgen's rare autoimmune disease drug, Tavneos, citing a lack of benefits that outweigh its risks.
Amgen (AMGN) Increases Despite Market Slip: Here's What You Need to Know
In the most recent trading session, Amgen (AMGN) closed at $351.93, indicating a +1.42% shift from the previous trading day.
Are Biosimilars Becoming a Key Pillar of Amgen's Growth Story?
AMGN's biosimilars business is driving growth, with new launches and a deep pipeline helping offset patent losses in key branded drugs.
